Alembic Pharmaceuticals has announced robust financial results for the year ended March 31, 2026. The company reported a significant increase in standalone annual revenue to ₹6,651.38 crore and a net profit of ₹640.42 crore. Reflecting this strong performance, the Board of Directors has recommended a final dividend of ₹12 per equity share, representing a 600% payout, subject to shareholder approval at the upcoming annual meeting.
Annual Financial Highlights
For the financial year 2025-26, Alembic Pharmaceuticals delivered solid growth. Standalone revenue from operations reached ₹6,651.38 crore, up from ₹6,032.63 crore in the previous year. The company’s annual profit after tax saw a healthy rise, climbing to ₹640.42 crore compared to ₹503.12 crore in 2024-25. This growth underscores the company’s resilience and effective operational management during the fiscal year.
Dividend Recommendation
In recognition of the company’s strong financial health and value creation, the Board of Directors has recommended a dividend of ₹12 per equity share for the financial year ended March 31, 2026. This dividend, which carries a face value of ₹2 per share, amounts to a 600% payout. This represents an increase over the previous year’s dividend of ₹11 per share (550%), demonstrating the company’s commitment to returning capital to its shareholders.
Operational Performance and Consolidated Results
On a consolidated basis, the company also reported impressive figures, with annual revenue reaching ₹7,344.90 crore and a net profit of ₹674.77 crore. The company continues to maintain a healthy balance sheet, with an improved net profit margin and disciplined management of its debt-equity ratios. Despite some one-time impacts related to labor code adjustments and asset write-downs, the underlying business trajectory remains strong, driven by consistent operational performance across its global portfolio.
Source: BSE
